Donor/recipient origin of lung cancer after lung transplantation by DNA short tandem repeat analysis

Frontiers in Oncology

Oncology

Justine Cohen¹  Yves Allory²  Morgan Leguen³  Alexandre Vallee⁴  Antoine Roux⁵  Abdul Hamid⁵  Edouard Robin⁶  Matthieu Glorion⁶  Julien De Wolf⁶  Edouard Sage⁷  Julien Masliah-Planchon⁸  Romane Beaurepere⁸  Ivan Bieche⁸ 

[1] Department of Anatomopathology, Foch Hospital, Suresnes, France;Department of Anatomopathology, Foch Hospital, Suresnes, France;Department of Anatomopathology, Curie Institut, Paris, France;Department of Anesthesiology, Foch Hospital, Suresnes, France;Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France;Department of Clinical Research and Innovation Foch Hospital, Suresnes, France;Department of Pneumology, Foch Hospital, Suresnes, France;Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France;Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France;Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France;Genetics Department, Curie Institut, Paris, France;

关键词: lung transplantation (LT);    short tandem repeat (STR);    desoxyribonucleic acid (DNA);    polymorphism chain reaction (PCR) transplantation;    lung cancer;    chimerism;    STR;    donor;   

DOI  :  10.3389/fonc.2023.1225538

 received in 2023-05-19, accepted in 2023-09-06,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundLung cancer is more common in posttransplant recipients than in the general population. The objective of this study was to examine the chimerism donor/recipient cell origin of graft cancer in recipients of lung transplant.MethodsA retrospective chart review was conducted at Foch Hospital for all lung transplantations from 1989 to 2020. Short tandem repeat PCR (STR-PCR) analysis, the gold standard technique for chimerism quantification, was used to determine the donor/recipient cell origin of lung cancers in transplant patients.ResultsFourteen (1.4%) of the 1,026 patients were found to have graft lung cancer after lung transplantation, and one developed two different lung tumors in the same lobe. Among the 15 lung tumors, 10 (67%) presented with adenocarcinoma, four (27%) with squamous cell carcinoma and one with small cell lung cancer. STR analysis showed that the origin of the cancer was the donor in 10 patients (71%), the recipient in three patients (21%), and was undetermined in one patient. Median time to diagnosis was 62 months.ConclusionThe prevalence of lung cancer in lung transplant recipients is very low. However, the results of our study showed heterogeneity of genetic alterations, with 21% being of recipient origin. Our results highlight the importance of donor selection and medical supervision after lung transplantation.

【 授权许可】

Unknown   
Copyright © 2023 De Wolf, Robin, Vallee, Cohen, Hamid, Roux, Leguen, Beaurepere, Bieche, Masliah-Planchon, Glorion, Allory, Sage and the Foch lung transplant group